8-K: Amedisys Acquired by UnitedHealth Group for $101/Share
Merger Completion
Amedisys, Inc. has completed its merger with UnitedHealth Group, becoming a wholly-owned subsidiary and delisting from Nasdaq, with shareholders receiving $101 per share in cash.
Summary
- Amedisys, Inc. completed its merger with Aurora Holdings Merger Sub Inc., a wholly-owned subsidiary of UnitedHealth Group Incorporated, on August 14, 2025.
- Amedisys is now a wholly-owned subsidiary of UnitedHealth Group.
- Each share of Amedisys common stock was converted into the right to receive $101 in cash, without interest.
- Outstanding equity awards (RSUs, PSUs, Options) were converted into equivalent awards of UnitedHealth Group common stock, generally retaining original terms. Director RSU awards were canceled for cash.
- Amedisys terminated its Senior Credit Facilities, paying an aggregate of $399,191,391.35 to satisfy all outstanding obligations.
- Amedisys common stock has been delisted from Nasdaq, and the company intends to deregister its common stock and suspend its reporting obligations with the SEC.
Sentiment
Score: 8
Explanation: The sentiment is highly positive for Amedisys shareholders who received a significant cash premium for their shares. For the company itself, the completion of the merger signifies a successful strategic exit and integration into a larger, well-resourced entity, resolving its independent public reporting obligations and debt.
Positives
- Completion of the merger provides Amedisys shareholders with a cash payout of $101 per share.
- Resolution of outstanding debt obligations through a $399,191,391.35 payment.
- Integration into a larger healthcare entity, UnitedHealth Group, potentially offering greater resources and stability for Amedisys's operations.
Negatives
- Amedisys common stock has been delisted from Nasdaq, removing its public trading status.
- The company will cease to be a publicly reporting entity, reducing transparency for former public shareholders.
- Existing Amedisys shareholders no longer hold equity in the independent company.
Future Outlook
Amedisys, Inc. will operate as a wholly-owned subsidiary of UnitedHealth Group Incorporated. Its common stock is delisted, and it will cease to be a publicly reporting company, shifting its operational and financial reporting within the larger parent company's structure.
Industry Context
This acquisition signifies further consolidation within the U.S. healthcare sector, particularly in the home health and hospice care market. UnitedHealth Group's acquisition of Amedisys strengthens its position in value-based care and in-home services, aligning with broader industry trends towards integrated care delivery and managing healthcare costs through preventative and post-acute care.
Comparison to Industry Standards
- The acquisition price of $101 per share for Amedisys represents a premium typical for strategic acquisitions in the healthcare sector, reflecting the value placed on Amedisys's market position and operational capabilities in home health and hospice.
- The immediate delisting and cessation of public reporting are standard procedures for a company becoming a wholly-owned subsidiary, aligning with practices seen in similar large-scale corporate integrations (e.g., CVS Health's acquisition of Aetna, or Centene's acquisition of WellCare Health Plans).
- The termination of existing credit facilities and the payment of outstanding debt are common financial maneuvers in such transactions, ensuring a clean balance sheet for the acquired entity under new ownership.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Paul B. Kusserow | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Julie D. Klapstein | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Richard Ashworth | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Vickie L. Capps | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Molly Coye, MD | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Teresa L. Kline | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Bruce D. Perkins | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Jeffrey A. Rideout, MD | NA | 2025-08-14 | Resigned in connection with the merger. |
| Director | Ivanetta D. Samuels | NA | 2025-08-14 | Resigned in connection with the merger. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Incorporation Amendment | The Certificate of Incorporation was amended and restated in its entirety, reducing the authorized shares to 1,000 common shares with a $0.01 par value, reflecting the company's new status as a private subsidiary. It also includes provisions for director liability limitation and indemnification. | 2025-08-14 | Significantly alters the corporate structure to align with its new status as a wholly-owned subsidiary, removing public company requirements and shareholder rights associated with publicly traded stock. |
| Bylaws Amendment | The Bylaws were amended and restated in their entirety, detailing new rules for stockholder meetings (including remote options), director powers, officer roles, capital stock management, dividends, and extensive indemnification provisions. It also states the corporation shall have no seal. | 2025-08-14 | Streamlines internal governance for a private subsidiary, removing provisions relevant to public shareholder engagement and aligning operational procedures with the parent company's control. |
Stakeholder Impact
- Shareholders: Received a cash payout of $101 per share, concluding their investment in Amedisys.
- Employees: Amedisys continues as a subsidiary of UnitedHealth Group, implying continuity of operations and employment under new ownership, though specific employee impacts are not detailed.
- Creditors: Senior Credit Facilities were terminated and fully paid, resolving Amedisys's prior debt obligations.
- Customers: The merger is expected to integrate Amedisys's home health and hospice services into UnitedHealth Group's broader healthcare offerings, potentially impacting service delivery or access in the long term, though immediate changes are not specified.
Next Steps
- Filing of Form 25 with the SEC to delist Amedisys Common Stock from Nasdaq and deregister under Section 12(b) of the Exchange Act.
- Intention to file Form 15 with the SEC to deregister Amedisys Common Stock under Section 12(g) and suspend reporting obligations under Section 15(d) of the Exchange Act.
Key Dates
| Date | Description |
|---|---|
| 2018-06-29 | Original date of Amended and Restated Credit Agreement. |
| 2019-02-04 | Date of First Amendment to Amended and Restated Credit Agreement. |
| 2021-07-30 | Date of Second Amendment to Amended and Restated Credit Agreement. |
| 2023-03-10 | Date of Third Amendment to Amended and Restated Credit Agreement. |
| 2023-06-26 | Date of the Agreement and Plan of Merger between Amedisys, UnitedHealth Group, and Merger Sub. |
| 2024-12-26 | Date of Waiver Letter modifying the Merger Agreement. |
| 2025-04-17 | Date of Fourth Amendment to Amended and Restated Credit Agreement. |
| 2025-08-14 | Effective Time and closing date of the merger; termination of Senior Credit Facilities; delisting notification to Nasdaq; resignations of Board members; effective date of amended Certificate of Incorporation and Bylaws. |
Recommendation
sellThe merger has closed, and Amedisys common stock has been converted into a cash payment of $101 per share. The stock is being delisted from Nasdaq, and the company will cease to be publicly traded. Therefore, there is no longer a market for Amedisys shares, and shareholders have received their final consideration. The recommendation is to sell any remaining shares if the conversion has not yet fully processed, or acknowledge the completed sale if it has.
Keywords
Amedisys, UnitedHealth Group, Merger, Acquisition, Home Health, Healthcare, Delisting, 8-K, Corporate Governance, Shareholder Payout, Debt Termination
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.